New Non Executive Director appointed to Shire Board

14th Nov 2005 12:03

New Non Executive Director appointed to Shire BoardBasingstoke, UK and Philadelphia, US - November 14, 2005 - The Board ofDirectors of Shire Pharmaceuticals Group plc (LSE: SHP, NASDAQ: SHPGY, TSX:SHQ) announces that Patrick Langlois will join as a Non Executive Director anda member of the Audit Committee with immediate effect.Patrick Langlois was with Aventis S.A., Strasbourg where he was most recentlyVice Chairman of the Management Board, having been Group Executive VicePresident, Chief Financial Officer for several years. Prior to this, he spentmany years in senior financial roles with the Rhone-Poulenc Group includingthree years as a member of the Executive Committee and Chief Financial Officer.Mr Langlois is a non-executive director of Coley Pharmaceuticals Group,Inc. and was a non-executive director of Rhodia SA between December 2002 andApril 2005.Dr James Cavanaugh, Chairman of Shire said:"Mr Langlois will bring welcome additional expertise to the Shire Board. Inparticular we will benefit from his wealth of experience in financial andoperational management within the global pharmaceutical industry."Patrick Langlois said:"I am pleased to be able to bring my knowledge and experience to Shire, one ofthe most exciting specialty pharmaceutical companies in the industry today. TheCompany is very well positioned for the future and I look forward to making asignificant contribution."Mr Langlois is a French national, lives in Paris and has worked in the US for11 years. He has a Ph.D in Economics (France) and a diploma in Banking Studies"For further information please contact:Investor Relations Clĩa Rosenfeld (Rest of the World) +44 1256 894 160 Brian Piper (North America) +1 484 595 8252 Media Jessica Mann (Rest of the World) +44 1256 894 280 Matthew Cabrey (North America) +1 484 595 8248 Notes to editorsShire Pharmaceuticals Group plcShire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceuticalcompany with a strategic focus on meeting the needs of the specialist physicianand currently focuses on developing and marketing products in the areas ofcentral nervous system (CNS), gastrointestinal (GI), renal diseases and humangenetic therapies. Shire has operations in the world's key pharmaceuticalmarkets (US, Canada, UK, France, Italy, Spain and Germany) as well as aspecialist drug delivery unit in the US.For further information on Shire, please visit the Company's website: www.shire.com."SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF1995Statements included herein that are not historical facts are forward-lookingstatements. Such forward-looking statements involve a number of risks anduncertainties and are subject to change at any time. In the event such risks oruncertainties materialize, Shire's results could be materially affected. Therisks and uncertainties include, but are not limited to, risks associated withthe inherent uncertainty of pharmaceutical research, product development,manufacturing and commercialization, the impact of competitive products,including, but not limited to, the impact of those on Shire's Attention Deficitand Hyperactivity Disorder (ADHD) franchise, patents, including, but notlimited to, legal challenges relating to Shire's ADHD franchise, governmentregulation and approval, including, but not limited to, the expected productapproval dates of MTS (METHYPATCH) (ADHD), SPD503 (ADHD), SPD465 (ADHD), SPD476(ulcerative colitis), I2S (idursulfase) (Hunter syndrome), Dynepo and NRP104(ADHD), including its scheduling classification by the Drug EnforcementAdministration in the United States, Shire's ability to benefit from itsacquisition of TKT, Shire's ability to secure new products forcommercialization and/or development and other risks and uncertainties detailedfrom time to time in Shire's filings with the Securities and ExchangeCommission, including its Annual Report on Form 10-K for the year to December31, 2004. Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com Press Release FOR IMMEDIATE RELEASE Registered in England 2883758 Registered Office as aboveENDShire Pharmaceuticals Group PLC

---

Related Shares:

Shire